Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1981 Jul;104(1):35–40.

Short-Term Effects of Vitamin D3 and 1,25-Dihydroxyvitamin D3 on Osteomalacia in Uremic Rats Fed a Low-Calcium-Low-Phosphorus Diet

Steven E Weisbrode
PMCID: PMC1903744  PMID: 6266257

Abstract

The objectives of this study were to evaluate the effects of vitamin D3 (D3) and 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on uremic bone disease independent of their action on the intestine. The histomorphology of tibial metaphyses in uremic (5/6 nephrectomized [5/6 Nx]) rats fed a low-calcium-low-phosphorus (LCLP) diet was compared with sham-operated (SO) rats fed an LCLP diet and 5/6 Nx rats fed an LCLP diet and given 15,000 IU D3 or 5 units (135 ng) 1,25-(OH)2D3 daily for 7 days. A marked osteomalacia characterized by an increased percentage of active and inactive trabecular osteoid surface and thickened growth plates developed in proximal tibial metaphyses in 5/6 Nx rats given the placebo, compared with SO rats. These bone changes were associated with relative hypophosphatemia, hypophosphaturia, and hypercalciuria in 5/6 Nx rats. In 5/6 Nx rats treated with D3 or 1,25-(OH)2D3 the growth plates had undergone mineralization and vascular invasion and were markedly reduced in thickness. Other parameters of osteomalacia in trabecular bone were not different from 5/6 Nx rats given the placebo. There was a significant decrease in osteoclasts per millimeter of trabecular surface perimeter in D3- and 1,25-(OH)2D3-treated rats. These bone changes were associated with hypercalcemia, hyperphosphatemia, and hyperphosphaturia, compared with 5/6 Nx rats given the placebo. It was concluded that in uremic rats fed the LCLP diet, shortterm treatment with either pharmacologic levels of D3 or 1,25-(OH)2D3 corrected only lesions in the growth plate. Osteoid seams were not reduced in treated rats, although the serum calcium-phosphorus product was elevated. The 5/6 Nx rat fed the LCLP diet appears to be a useful model for the rapid induction of uremic osteomalacia in adult animals.

Full text

PDF
35

Images in this article

38Figure 1
on p.38
39Figure 2
on p.39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed K. Y., Varghese Z., Wills M. R., Meinhard E. A., Moorhead J. F. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Lancet. 1978 Mar 25;1(8065):629–632. doi: 10.1016/s0140-6736(78)91137-6. [DOI] [PubMed] [Google Scholar]
  2. Bayard F., Bec P., Ton That H., Louvet J. P. Plasma 25-hydroxycholecalciferol in chronic renal failure. Eur J Clin Invest. 1973 Dec;3(6):447–450. doi: 10.1111/j.1365-2362.1973.tb02213.x. [DOI] [PubMed] [Google Scholar]
  3. Bordier P. J., Marie P. J., Arnaud C. D. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Kidney Int Suppl. 1975 Jan;(2):102–112. [PubMed] [Google Scholar]
  4. Brickman A. S., Sherrard D. J., Jowsey J., Singer F. R., Baylink D. J., Maloney N., Massry S. G., Norman A. W., Coburn J. W. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy. Arch Intern Med. 1974 Nov;134(5):883–888. doi: 10.1001/archinte.134.5.883. [DOI] [PubMed] [Google Scholar]
  5. Chen T. C., Castillo L., Korycka-Dahl M., DeLuca H. F. Role of vitamin D metabolites in phosphate transport of rat intestine. J Nutr. 1974 Aug;104(8):1056–1060. doi: 10.1093/jn/104.8.1056. [DOI] [PubMed] [Google Scholar]
  6. Cochran M., Nordin B. E. Role of acidosis in renal osteomalacia. Br Med J. 1969 May 3;2(5652):276–279. doi: 10.1136/bmj.2.5652.276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eastwood J. B., Bordier P. J., de Wardener H. E. Some biochemical, histological, radiological and clinical features of renal osteodystrophy. Kidney Int. 1973 Aug;4(2):128–140. doi: 10.1038/ki.1973.91. [DOI] [PubMed] [Google Scholar]
  8. Eastwood J. B., Bordier P., de Wardener H. E. Comparison of the effect of vitamin D and calcium carbonate in renal osteomalacia. Q J Med. 1971 Oct;40(160):569–570. [PubMed] [Google Scholar]
  9. Eastwood J. B., Stamp T. C., Harris E., de Wardener H. E. Vitamin-D deficiency in the osteomalacia of chronic renal failure. Lancet. 1976 Dec 4;2(7997):1209–1211. doi: 10.1016/s0140-6736(76)91140-5. [DOI] [PubMed] [Google Scholar]
  10. Fournier A., Bordier P., Gueris J., Sebert J. L., Marie P., Ferrière C., Bedrossian J., DeLuca H. F. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int. 1979 Feb;15(2):196–204. doi: 10.1038/ki.1979.25. [DOI] [PubMed] [Google Scholar]
  11. Galante L., Colston K. W., Evans I. M., Byfield P. G., Matthews E. W., MacIntyre I. The regulation of vitamin D metabolism. Nature. 1973 Aug 17;244(5416):438–440. doi: 10.1038/244438a0. [DOI] [PubMed] [Google Scholar]
  12. Goldner J. A modification of the masson trichrome technique for routine laboratory purposes. Am J Pathol. 1938 Mar;14(2):237–243. [PMC free article] [PubMed] [Google Scholar]
  13. Henderson R. G., Russell R. G., Ledingham J. G., Smith R., Oliver D. O., Walton R. J., Small D. G., Preston C., Warner G. T. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet. 1974 Mar 9;1(7854):379–384. doi: 10.1016/s0140-6736(74)93149-3. [DOI] [PubMed] [Google Scholar]
  14. Krempien B., Ritz E. Experimental renal osteopathy. Isr J Med Sci. 1971 Mar;7(3):522–524. [PubMed] [Google Scholar]
  15. Massry S. G., Tuma S., Dua S., Goldstein D. A. Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites: evidence for the requirement of 1,25(OH)2D3 and 24,25(OH)2D3. J Lab Clin Med. 1979 Jul;94(1):152–157. [PubMed] [Google Scholar]
  16. Mawer E. B., Taylor C. M., Backhouse J., Lumb G. A., Stanbury S. W. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet. 1973 Mar 24;1(7804):626–628. doi: 10.1016/s0140-6736(73)92197-1. [DOI] [PubMed] [Google Scholar]
  17. Miller S. C., Jee W. S. Ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Effects on growth and modeling of the rat tibia. Calcif Tissue Res. 1975 Sep 5;18(3):215–231. doi: 10.1007/BF02546241. [DOI] [PubMed] [Google Scholar]
  18. Steele T. H., Engle J. E., Tanaka Y., Lorenc R. S., Dudgeon K. L., DeLuca H. F. Phosphatemic action of 1,25-dihydroxyvitamin D3. Am J Physiol. 1975 Aug;229(2):489–495. doi: 10.1152/ajplegacy.1975.229.2.489. [DOI] [PubMed] [Google Scholar]
  19. Weisbrode S. E., Capen C. C. Model for skeletal resistance to vitamin D in renal failure. Fed Proc. 1976 Apr;35(5):1225–1231. [PubMed] [Google Scholar]
  20. Weisbrode S. E., Capen C. C. Morphometric analysis of skeletal response to vitamin D in uremic rats fed a low calcium diet. Virchows Arch B Cell Pathol Incl Mol Pathol. 1979 Jun 29;30(3):275–280. doi: 10.1007/BF02889107. [DOI] [PubMed] [Google Scholar]
  21. Weisbrode S. E., Capen C. C., Nagode L. A. Ultrastructural evaluation of the effects of vitamin D and uremia on bone in the rat. Am J Pathol. 1974 Aug;76(2):359–376. [PMC free article] [PubMed] [Google Scholar]
  22. Weisbrode S. E., Capen C. C., Norman A. W. Ultrastructural evaluation of the effects of 1,25-dihydroxyvitamin D3 on bone of thyroparathyroidectomized rats fed a low-calcium diet. Am J Pathol. 1978 Aug;92(2):459–472. [PMC free article] [PubMed] [Google Scholar]
  23. Weisbrode S. E., Capen C. C. Vitamin D-induced hypercalcemia in experimental renal failure. Nephron. 1977;18(1):26–34. doi: 10.1159/000180763. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES